top of page

Finland adopts New Act on Clinical Trials Legislation (FIMEA)

Writer's picture: Sharan MuruganSharan Murugan

The Parliament of Finland has adopted a new Act on Clinical Trials on 8 October 2021. The Parliament also approved amendments to the Medical Research Act. The amendments to the Medical Research Act aim to align the legislation on medical research with the regulations concerning clinical trials.


These amendments to Finnish legislation will enter into force at the same time as a relevant EU regulation, on 31 January 2022. However, provisions on the processing of personal data will enter into force before this date.

The Act on Clinical Trials contains provisions on the matters governed by a relevant EU regulation, making national regulation in Finland possible.

These matters include:

· the qualifications of a researcher carrying out a clinical trial

· the language of application documents

· certain conditions for trials involving vulnerable populations

· main principles for the assessment responsibilities of Fimea and the ethics committee

· principles of fees for sponsors and compensation paid to subjects

· matters related to the processing of personal data in clinical trials

· matters related to the supervision of clinical trials

The Act also contains provisions on matters related to the processing of applications for clinical trials during the EU regulation on clinical trials (536/2014).

The EU regulation on clinical trials (536/2014) will enter into force 31 January 2022, which is when the now approved Act on Clinical Drug Trials will also enter into force. However, provisions on the processing of personal data will enter into force before this date.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page